Substance / Medication

Retigabine

Overview

Active Ingredient
ezogabine
RxNorm CUI
1112990

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effect of a single dose of retigabine in cortical excitability parameters: A cross-over, double-blind placebo-controlled TMS study.
Ossemann Michel, de Fays Katalin, Bihin Benoit et al. · Epilepsy Res · 2016
PMID: 27448328RCT
Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures.
Biton Victor, Gil-Nagel Antonio, Brodie Martin J et al. · Epilepsy Res · 2013
PMID: 24094693RCT
Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events.
Brickel Neil, Hewett Karen, Rayner Kirsty et al. · Epilepsy Behav · 2020
PMID: 31731109Observational
Micelle and inclusion complex enhanced spectrofluorimetric methods for determination of Retigabine: Application in pharmaceutical and biological analysis.
Mostafa Aya M, Rageh Azza H, Ali Marwa F B et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2019
PMID: 30248612Observational
Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
Kovalchuk Maria O, Heuberger Jules A A C, Sleutjes Boudewijn T H M et al. · Clin Pharmacol Ther · 2018
PMID: 29672831Observational
Effects of novel subtype selective M-current activators on spinal reflexes in vitro: Comparison with retigabine.
Vicente-Baz Jorge, Lopez-Garcia Jose A, Rivera-Arconada Ivan · Neuropharmacology · 2016
PMID: 27263036Observational
Comparison of the long-term behavioral effects of neonatal exposure to retigabine or phenobarbital in rats.
Frankel Sari, Medvedeva Natalia, Gutherz Samuel et al. · Epilepsy Behav · 2016
PMID: 26921596ObservationalFull text (PMC)
Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany.
Nass R D, Kurth C, Kull A et al. · Epilepsy Behav · 2016
PMID: 26828693Observational
A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy.
Huber Bernd, Bocchicchio Michelina · Epilepsy Behav · 2015
PMID: 25836054Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Retigabine (substance)
SNOMED CT
699271005
UMLS CUI
C0530684
RxNorm CUI
1112990

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.